MUMBAI, India, Oct. 26 -- Intellectual Property India has published a patent application (202611112095 A) filed by Noida Institute Of Engineering And Technology Pharmacy Institute on September 18, 2026, for Cd44-Targeted Magneto-Sonoresponsive Nanocapsule For Platinum-Resistant Ovarian Carcinoma.
Inventors include Dr. Priyanka Bansal; and Anmol Dogra.
The application for the patent was published on October 23, 2026, under issue no. 43/2026.
Abstract: The present invention discloses a CD44-targeted magneto-sonoresponsive polymer-lipid hybrid nanocapsule having a diameter of 100 to 150 nanometres for platinum- resistant ovarian carcinoma. The nanocapsule comprises a superparamagnetic iron-oxide core embedded in a perfluorohexane sonosensitive phase, a poly(lactic-co- glycolic acid)-poly(ethylene glycol) interlayer, and a phospholipid bilayer incorporating an ionizable arginine-cholesterol carbamate amphiphile having a pKa of 6.5. A pH-cleavable oxaliplatin(IV) hydrazone prodrug and curcumin-piperine chemosensitizer are co-encapsulated within the nanocapsule, which further comprises a hyaluronic-acid CD44-targeting shell and a grape-seed proanthocyanidin corona. A protein-based immuno-lateral-flow cartridge enables stratification based on CD44, P-glycoprotein and glutathione-S-transferase-pi expression. The formulation demonstrated a twelve-fold reduction in platinum inhibitory concentration, a Chou-Talalay combination index of 0.31, and 78% tumour-volume reduction in a platinum-resistant ovarian xenograft.
Disclaimer: Curated by HT Syndication.
